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INTRODUCTION
Cyclophosphamide (CP) is an extensively used as an anti-
cancer and immunosuppressive agent (1, 2). However, the
urologic side effects of CP have been reported to range from
asymptomatic microhematuria to life-threatening hemor-
rhagic cystitis (3, 4). CP also induces chronic bladder inflam-
mation in experimental animal models that resemble the
clinical syndrome of interstitial cystitis (5). 
CP causes mucosal ulceration, transmural edema and epithe-
lial necrosis that are associated with acute hemorrhage (6,
7). Vigorous diuresis and agents that can detoxify CP, such
as 2-mercaptoethene sulfate (MESNA), have been used to
decrease the urotoxicity (8). However, despite the positive
results after the prophylactic use of MESNA, bladder pro-
tection is not always achieved (8, 9). Hemorrhagic cystitis
still occurs after CP administration. It is important to inves-
tigate the basic mechanisms involved in the destruction of
the uro-epithelial barrier in CP induced cystitis. However,
it is not clear which mechanisms are actively involved in
incurring mucosal damage. 
The mammalian bladder maintains high electrochemical
gradients between the urine and blood (10). The apical mem-
brane in the bladder mucosa contains a group of four related
transmembrane proteins; the uroplakins (UPs), which togeth-
er with tight junctions form a specialized membrane com-
partment that represents one of the tightest and most imper-
meable barriers in the body (11-13). We formed a hypothe-
sis that when the UPs are damaged by toxic materials, urine
leaks into the underlying bladder layers and this induced
inflammatory reactions in the bladder wall. 
Studies have recently been done concerning the mechanisms
involved in the pathogenesis of experimental alkylating agent-
induced urologic complications (14, 15). Although much
has been learned about the molecular changes, as well as some
aspects of their physiological significance in the uro-epithe-
lium, relatively little is known about the UPs’ function when
they are exposed to noxious chemicals. 
In the current studies we investigated whether UPs were
actively involved in the pathogenesis of CP-induced urothe-
lial toxicity in mice. For this purpose we analyzed the time-
ly expression of uroplakin Ia, Ib, II, and III in CP induced
mouse cystitis. 
MATERIALS AND METHODS
The present animal study protocol was approved by the
IACUC of Dankook University College of Medicine. A total
of 27 female ICR mice received an intramuscular injection
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Expressions of Uroplakins in the Mouse Urinary Bladder with
Cyclophosphamide-Induced Cystitis
Even though uroplakins (UPs) are believed to serve a strong protective barrier against
toxic materials, cyclophosphamide (CP) causes extensive cystitis. We investigated
the expression of UPs in the urothelium in CP induced mouse cystitis. A total of 27
ICR female mice received a single intraperitoneal injection of 200 mg CP/kg. Nine
CP-treated mice and 6 controls were sequentially killed at 12, 24, and 72 hr post
injection. Extensive cystitis and an increased vesical weight were seen. These all
peaked within 12 hr post injection and they tended to decrease thereafter. The level
of all the UPs mRNA, the protein expressions of UP II and III on immunoblotting
study, and the expression of UP III on immunolocalization study were maximally
suppressed within 12 hr; this partially recovered at 24 hr, and this completely recov-
ered at 72 hr post CP injection. In conclusion, CP reduced the expression of UPs.
The reduction of the UPs mRNA and protein was time dependent, and this peaked
within 12 hr after CP injection. However, the damage was rapidly repaired within 24
hr. This study demonstrates a dynamic process, an extensive reduction and rapid
recovery, for the UPs expression of the mouse urinary bladder after CP injection. 
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of ketamine (15 mg/kg) and xylazine (5 mg/kg), and then
they received an intraperitoneal injection of 200 mg CP/kg
(Sigma Chemicals, St. Louis, MO, U.S.A.) dissolved in dis-
tilled water (7). Eighteen mice (control group) received ster-
ile water only. Nine CP-treated mice and 6 controls were sac-
rificed at 12, 24, and 72 hr post injection, respectively. The
mice’ bladders were removed and weighed. At each time,
three treated mice bladders and two control bladders were
fixed with 4% paraformaldehyde for immunohistochemistry,
whereas six treated mice bladders and four control bladders
were stored within a deep freezer. 
Reverse transcription polymerase chain reaction (RT-PCR)
The total RNA was extracted from the whole bladder spec-
imen with using Trizol reagent (Invitrogen, Carlsbad, CA,
U.S.A.) and chloroform. We designed the PCR primers for
all the uroplakins that spanned at least one intron of the cor-
responding genes. The primers synthesized for β -actin were
5′ -TGG AAT CCT GTG GCA TCC ATG AAA C-3′ and
5′ -TAA AAC GCA GCT CAG TAA CAG TCC G-3′ accord-
ing to the known cDNA sequence (GenBank code: NM00-
7393). The primers for uroplakin Ia were 5′ -TGT CGT CGT
CGG TAC ATG AT-3′ and 5′ -CAG AGT CGG GTT AGC
TCC TG-3′ (GenBank code: NM081091). The primers for
uroplakin Ib were 5′ -CCT CTT CTG CTT GTC CGT TC-
3′ and 5′ -CTG CTT CAG GAA GAG GTT GG-3′ (Gen-
Bank code: NM178924). The primers for uroplakin II were
5′ -AGA GCC AAC GAC AGC AAA GT-3′ and 5′ -GGT
GTA GCC AGA CCC ACT GT-3′ (GenBank code: NM-
009476). The primers for uroplakin III were 5′ -CTG ACC
CCT TGT GGT GAC TT-3′ and 5′ -GGA CGT GAT GAC
AAT CAT GC-3′ (GenBank code: AF222750). We used the
ImProm-IITM Reverse Transcription System (Promega, Madi-
son, WI, U.S.A.) to prepare cDNA according to the manu-
facture’s introduction. PCR was performed with 25 μ L of the
following reaction mixture: 12.5 μ L of 2x GoTaq Green Mas-
ter mixture (Promega), 10 pM of each primer and 1 μ L of the
DNA template. The amplification conditions were as follows:
each step consisted of denaturation at 95℃for 30 sec, anneal-
ing at 53℃for 30 sec and extension at 72℃for 30 sec. Thir-
ty cycles for amplification were performed. The amplified
products were resolved by electrophoresis through 2% agarose
gels and then they were stained with ethidium bromide; the
images were digitally captured using LAS 3000 software (Fuji-
film, Tokyo, Japan).
Western blotting
We prepared the whole bladder lysate in lysis solution (50
mM Tris-Cl [pH7.5], 250 mM NaCl, 0.5% Triton x-100, 1
mM DTT, 1 mM EDTA, 1 mM PMSF, 1 mM Na3VO4, 10%
glycerol and 2 μ g/mL each of aprotinin, leupeptin and anti-
pain). The amount of loaded proteins for uroplakin II and III
were 30 μ g each. The proteins were separated by 15% SDS-
polyacrylamide gel electrophoresis, and they were transferred
to nitrocellulose membranes. After incubation with 5% skim
milk in TBST (10 mM Tris-Cl [pH7.5], 100 mM NaCl, 0.1%
Tween20) for 1 hr at room temperature, the membrane was
incubated with goat polyclonal primary antibody (uroplakin
II, III. 1:1,000 dilutions) (Santa Cruz Biotechnology, Santa
Cruz, CA, U.S.A.) in 5% skim milk in TBST solution for
overnight at 4℃. After washing with TBST solution, the
membranes were incubated with the secondary antibody (don-
key anti-goat IgG-HRP polyclonal antibody, 1:2,500 dilu-
tions) (Santa Cruz) for 1 hr at room temperature. After exten-
sively washing, the membranes were enhanced with western
blotting liminol reagent (Santa Cruz) for 1 min, and they
were exposed from 30 sec to 30 min and the pictures were
taken using a LAS-3000 image reader (Fujifilm). 
Immunohistochemistry
The paraffin blocks were deparaffinized in xylene and alco-
hol. The antigens were retrieved by heating the specimens
for 10 min at 121℃ in TE buffer (10 mMTris-HCl, 1 mM
EDTA, pH 7.8), and the endogenous avidin binding sites
in the urothelium were blocked with using 10% skim milk
in TBST solution for 1 hr. Immunolabeling with anti-uro-
plakin III polyclonal antibody (Santa Cruz) at a 1:100 dilu-
tion was performed in 10% skim milk in TBST solution. The
rabbit anti-goat immunoglobins HRP (Zymed, South San
Francisco, CA, U.S.A.) at a 1:500 dilution was used for the
secondary antibody. The peroxidase activity was demonstrat-
ed with 3,3′ -diaminobenzidine. The sections were counter-
stained with Mayer haematoxylin, and then they were dehy-
drated and mounted. 
RESULTS
A single dose of CP caused mucosal injury in the urothe-
lium, and this was followed by a regenerative process. Sig-
nificant increases in bladder wet weight were noted within
12 hr post injection, and this tended to decrease thereafter.
When compared with normal bladder (Fig. 1A), the blad-
der revealed extensive cystitis that was characterized by acute
inflammation with vascular congestion, edema and hemor-
rhage at 12 hr post injection (Fig. 1B). However, the submu-
cosal edema was reduced at 24 hr (Fig. 1C) and the urothe-
lium almost completely restored at 72 hr (Fig. 1D). A strong
uroplakin III expression appeared along the bladder epithe-
lium in the control bladder (Fig. 2A). At 12 hr after CP injec-
tion, there was a significantly decrease or loss of the uroplakin
III expression in the intact bladder mucosa (Fig. 2B). How-
ever, this expression was weakly restored at 24 hr (Fig. 2C)
and it was completely recovered at 72 hr (Fig. 2D). The mes-
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cantly decreased after 12 hr and they completely recovered
at 24 hr post CP injection. The protein expressions of uro-
plakin II and III were significantly decreased after 12 hr and
they were restored 24 hr after CP injection (Fig. 3, 4).
DISCUSSION 
It is well known that acrolein, which is one of the metabo-
lites of CP in urine, contacts the urothelial mucosa and detach-
es the superficial cells. This may increase the bladder’s per-
meability, permitting increased access of the constituents in
the urine to the neurons and inflammatory cells in the mucosa
or submucosa (6, 16). However, there have been very few stud-
ies that have focused on explaining the interaction between
the toxic material and the bladder’s barrier. Moreover, previ-
ous animal studies with using CP have mainly focused on
the neurochemical and electrophysiological properties of the
bladder detrusor muscle or the afferent neurons in the blad-
der wall (5, 17, 18). 
The most characteristic feature of the terminally differen-
tiated superficial cells of the bladder mucosa is their unique
Fig. 1. Cyclophosphamide (CP) induced bladder histological alterations. (A) Normal epithelium projected to bladder lumen in controls. (B)
Histological section of the urinary bladder of mice showed epithelial ulceration, hemorrhage, and submucosal edema at 12 hr post CP injec-
tion. (C, D) Cystitis improved at 24 and 72 hr, respectively. Hematoxylin and eosinstaining. Original magnifications (A) ×40 and (B-D) ×10.
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apical plasma membrane, which is covered with rigid-look-
ing UPs. Four UPs (UP Ia, UP Ib, UP II, and UP III) have
been isolated and characterized, and they are considered to
be biochemical markers of urothelial differentiation and they
are biochemically unique (11, 12). Because these membranes
are unusually stable in a number of harsh conditions includ-
ing 2% NP-40, 2% sodium sarcosine, 25 mM NaOH, 9 M
urea and 6 M guanidium chloride, these membranes are be-
lieved to serve as an exceptionally effective permeability bar-
rier (11-13). As a result, we had a concern about the changes
of the molecular expression of the UPs, which are an ideal
urothelial protector, when they are insulted by CP.
Two mechanisms may be possible. First, the toxic metabo-
lites contact to the uroepithelium and they mechanically de-
stroy the epithelium. Toxic materials and water freely pass
through the defect and accumulate into the submucosa. Sec-
ond, CP directly suppresses the expression of UPs in the uro-
epithelium by unknown mechanisms, and this diminishes
or weakens the barrier function of the urothelium and there
is passive accumulation of water into the submucosal area.
Fig. 2. Immunohistochemical reaction with anti-uroplakin III antibody. (A) A strong uroplakin III expression appeared along the bladder
epithelium in control bladder. (B) At 12 hr after cyclophosphamide injection, there was a significantly decrease or loss of uroplakin III expres-
sion in intact bladder mucosa (arrows). (C, D) However, the expression was weakly restored at 24 hr and completely recovered at 72 hr.
All original magnifications were x10. 
A B
C D688 S.H. Choi, Y. Byun, and G. Lee
Our finding was a little different from a previous study for
which the maximal damage in the bladder mucosa was noted
at 48 hr, and normal morphological restoration was noted
within 7-10 days after CP injection (19). We think these
differences may have been caused by using a different model
or a different CP dosage.
Terminal differentiation in the apical plasma membrane
takes place within the superficial layer of cells that are char-
acterized by the presence of UPs. Since urothelial plaques and
their subunits, i.e. the UPs, are synthesized in large quanti-
ties by only the terminally differentiated urothelial cells, the
UPs can be regarded as a major urothelial differentiation prod-
uct (12, 20). Fig. 2A shows that the expression of uroplakin
III is uniquely distributed in a dense layer that’s concentrat-
ed on the luminal surface of the umbrella cells in the urothe-
lium. Interestingly, the protein expression of UP III was mar-
kedly reduced in the apical membrane within 12 hr after CP
injection. However, the loss of UP III was time limited. It
was partially recovered within 24 hr after CP treatment and
it completely recovered at 72 hr. This finding matched with
Veranic et al.’s study (20). They revealed that a generalized
denuded urothelium was found after CP injection. However,
focal intact microvilli were negative to anti-UP antibodies
on their apical surfaces at day 1 after CP injection. We also
can found the same finding on Fig. 2B. Even though a large
area of urothelium was gone with CP injection, some focal
intact uroepithelium showed a significantly loss of uroplakin
III expression. With above findings we can confirm the hy-
pothesis that CP may actively depress the expression of UPs
in uroepithelium when are damaged by CP. 
From days 1-4 days, epithelial cells with weak anti-UP
labeling were seen and this phenomenon was not limited to
a single UP, but all UPs were simultaneously reduced on the
electron microscope images (20). Even though we used only
one antibody, UP III, we believe that immunohistochemical
staining with UP Ia, Ib, and II antibodies may reveal the same
findings. The morphologic and immunohistochemical stud-
ies were also supported by the mRNA expression study and
the western blotting study. The mRNA expressions of all the
UPs were maximally reduced at 12 hr after CP injection, and
these expressions were recovered at 24 hr. We tried using all
the UPs antibodies. It was very difficult to get good bands
from using the anti-UP Ia and Ib antibodies. We estimated
this finding may be due to a structural uniqueness, the tetra-
spanin family, in UP Ia and Ib. The protein levels of UP II
and III were maximally decreased at 12 hr after CP injection,
and they were restored thereafter. 
The ablation of UP III led to abnormal synthesis and pro-
cessing of UP Ib, i.e., the level of UP Ib mRNA was greatly
increased, whereas the amount of UP Ib protein was reduced.
Because UP III and UP Ib are known to interact, these UP
Ib changes were caused by the removal of its partner, UP III
(13, 21). The UP II ablation led to an up-regulation of the UP
Ib mRNA level (21). However, our results showed that the
expressions of all the UPs were simultaneously reduced at the
mRNA and protein levels, which mean a different mecha-
nism may be involved. 
A number of conditions lead to disruption of the bladder
permeability barrier, with leakage of urine constituents into
the underlying cell layers. These include bacterial infection,
exposure to noxious chemicals and the dysplasia of tumor
growth (22, 23). In addition, interstitial cystitis is a chronic
painful condition of an unknown cause, and it is associated
with disruption of the permeability barrier in cats (24). Our
result may be helpful for understanding the injury and repair
mechanisms of the apical membrane. This may lead to impor-
tant insights for the care of patients with interstitial cystitis,
and this may also shed light on developing new drugs for
ameliorating the urotoxicity after cyclophosphamide-based
chemotherapy. 
In conclusion, CP induces actively down regulation of all
the UP genes, and this damages the urothelial protective bar-
rier in the early injured phase. However, the damaged urothe-
lium is rapidly recovered within 24 hr post injection. That
means rapid resealing of injuries to the bladder permeabili-
ty barrier is of major physiological importance to restore the
bladder’s protection. 
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